Tacrolimus Starting Dose Prediction Based on Genetic Polymorphisms and Clinical Factors in Chinese Renal Transplant Recipients,Genetic Testing and Molecular Biomarkers

当前位置： X-MOL 学术 › Genet. Test. Mol. Biomark. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Tacrolimus Starting Dose Prediction Based on Genetic Polymorphisms and Clinical Factors in Chinese Renal Transplant Recipients
Genetic Testing and Molecular Biomarkers ( IF 1.1 ) Pub Date : 2020-10-15 , DOI: 10.1089/gtmb.2020.0077
Peile Wang _{1,

2} , Qiwen Zhang _{1,

2} , Xueke Tian _{1,

2} , Jing Yang _{1,

2} , Xiaojian Zhang _{1,

2}

Affiliation

Aims: Tacrolimus has extensive pharmacokinetic variability among patients and a narrow therapeutic window. The U.S. Clinical Pharmacogenetics Implementation Consortium recommends a starting dose for tacrolimus of 0.15–0.3 mg/kg/day, which is much higher compared with 0.05–0.15 mg/kg/day used in China. The purpose of this study was to investigate the influence of clinical factors and single nucleotide polymorphisms (SNPs) on tacrolimus concentrations in Chinese renal transplant recipients.

更新日期：2020-10-17

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11